Avin Pothuloori, MD
Endocrinology, Diabetes & Metabolism · North Kansas City, MONPI 1245523141
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Chiesi USA, Inc. at 59.3% of the total. 2025 is the largest year on record at $9,842, more than ten times the $160 reported in 2019.
Across 212 payments — averaging $63.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Chiesi USA, Inc.$8K
- BETA Bionics, Inc.$890
- Abbott$705
- Boehringer Ingelheim$471
- Bayer$438
- Lilly USA, LLC$394
- plus $3K from 25 others
What the payments were for
- Speaking & faculty fees$6,25047%
- Travel & lodging$1,0348%
- Food & beverage$6,11446%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Chiesi USA, Inc. | 18 | $7,960 |
| BETA Bionics, Inc. | 13 | $890 |
| Abbott | 15 | $705 |
| Boehringer Ingelheim | 16 | $471 |
| Bayer | 21 | $438 |
| Lilly USA, LLC | 34 | $394 |
| Corcept Therapeutics | 10 | $368 |
| Novo Nordisk | 10 | $355 |
| Recordati_rare_diseases_inc. | 12 | $279 |
| Medtronic(2 entities) | 6 | $246 |
| Sanofi-aventis U.S. LLC | 6 | $217 |
| Insulet Corporation | 2 | $150 |
| Xeris Pharmaceuticals, Inc. | 8 | $141 |
| Amgen(2 entities) | 8 | $136 |
| Radius Health, Inc. | 6 | $107 |
| Convatec Inc. | 1 | $98 |
| Pfizer | 4 | $88 |
| Ascensia Diabetes Care US Inc. | 3 | $54 |
| Madrigal Pharmaceuticals | 2 | $46 |
| Kyowa Kirin, Inc. | 2 | $38 |
| AstraZeneca(2 entities) | 2 | $35 |
| Sequel Med Tech, LLC | 2 | $31 |
| Neurocrine Biosciences, Inc. | 2 | $31 |
| Novartis | 2 | $28 |
| Averitas Pharma Inc. | 1 | $23 |
| Antares Pharma, Inc. | 1 | $20 |
| AbbVie | 1 | $19 |
| Ascendis Pharma Endocrinology Inc | 1 | $17 |
| Cequr Corporation | 1 | $17 |
| Tolmar, Inc. | 1 | $16 |
| Amryt Pharma Holdings Ltd | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MYCAPSSA$7,518
- iLet Bionic Pancreas$1,783
- FREESTYLE LIBRE 3$286
- iLet Insulin Infusion Kit Inset$258
- iLet Insulin Infusion Kit Contact Detach$258
- Omnipod$134
- TZIELD$120
- Korlym$120
- JARDIANCE$106
- MYALEPT$104
- JUXTAPID$104
- RYBELSUS$100
How this compares
$13,430 in reported general payments places this provider in the 80th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
See all endocrinology, diabetes & metabolism providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 155 | $184,223 |
| OzempicSemaglutide | 71 | $79,520 |
| JardianceEmpagliflozin | 63 | $74,121 |
| ForteoTeriparatide | 14 | $64,721 |
| TrulicityDulaglutide | 32 | $49,318 |
| Humalog Kwikpen U-200Insulin Lispro | 11 | $24,434 |
| KerendiaFinerenone | 27 | $23,503 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 16 | $20,605 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $17,200 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 73 | $13,795 |
| TradjentaLinagliptin | 14 | $13,710 |
| FarxigaDapagliflozin Propanediol | 14 | $11,483 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $10,920 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $10,111 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 11 | $9,486 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Forteo, Trulicity | $394 | $298,261201 claims |
| Boehringer IngelheimJardiance, Tradjenta | $471 | $87,83177 claims |
| Novo NordiskOzempic, Novolog | $355 | $81,77982 claims |
| BayerKerendia | $438 | $23,50327 claims |
| AstraZenecaFarxiga | $35 | $11,48314 claims |
| Sanofi-aventis U.S. LLCLantus | $217 | $5,15129 claims |
| AbbVieSynthroid | $19 | $2,80725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
Other endocrinology, diabetes & metabolism in North Kansas City
- Ralph DudaSpringfield$644K
- Karen Chang-ChenChesterfield$640K
- Alan RaubaJefferson City$594K
- Jerome ThurmanSaint Charles$312K
- Janet McGillSaint Louis$212K
- Megan WoodSt. Louis$207K
- Ralph OiknineChesterfield$144K
- Jonben SvobodaSpringfield$142K
- James BonucchiSpringfield$128K
- Christopher CaseJefferson City$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.